Advertisement

Clinical Pharmacokinetics

, Volume 54, Issue 1, pp 35–80 | Cite as

Pharmacokinetics and Pharmacokinetic–Pharmacodynamic Relationships of Monoclonal Antibodies in Children

  • Helena Edlund
  • Johanna Melin
  • Zinnia P. Parra-Guillen
  • Charlotte KloftEmail author
Review Article

Abstract

Monoclonal antibodies (mAbs) constitute a therapeutically and economically important drug class with increasing use in both adult and paediatric patients. The rather complex pharmacokinetic and pharmacodynamic properties of mAbs have been extensively reviewed in adults. In children, however, limited information is currently available. This paper aims to comprehensively review published pharmacokinetic and pharmacokinetic–pharmacodynamic studies of mAbs in children. The current status of mAbs in the USA and in Europe is outlined, including a critical discussion of the dosing strategies of approved mAbs. The pharmacokinetic properties of mAbs in children are exhaustively summarised along with comparisons to reports in adults: for each pharmacokinetic process, we discuss the general principles and mechanisms of the pharmacokinetic/pharmacodynamic characteristics of mAbs, as well as key growth and maturational processes in children that might impact these characteristics. Throughout this review, considerable knowledge gaps are identified, especially regarding children-specific properties that influence pharmacokinetics, pharmacodynamics and immunogenicity. Furthermore, the large heterogeneity in the presentation of pharmacokinetic/pharmacodynamic data limited clinical inferences in many aspects of paediatric mAb therapy. Overall, further studies are needed to fully understand the impact of body size and maturational changes on drug exposure and response. To maximise future knowledge gain, we propose a ‘Guideline for Best Practice’ on how to report pharmacokinetic and pharmacokinetic–pharmacodynamic results from mAb studies in children which also facilitates comparisons. Finally, we advocate the use of more sophisticated modelling strategies (population analysis, physiology-based approaches) to appropriately characterise pharmacokinetic–pharmacodynamic relationships of mAbs and, thus, allow for a more rational use of mAb in the paediatric population.

Keywords

Infliximab Maturation Process Omalizumab Daclizumab Basiliximab 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The authors wish to thank Corina Becker (Bayer Pharma) for fruitful discussion, Tamara Richter and Caroline Fongern (both Freie Universitaet Berlin) for their support during the literature search, and the reviewers of this manuscript for their valuable input into the manuscript. No sources of funding were used for the preparation of this review. The authors have no conflict of interest to declare.

References

  1. 1.
    Pharmaceutical Research and Manufacturers of America (PhRMA). Medicines in development. Biologics 2013 report. http://www.phrma.org/sites/default/files/pdf/biologics2013.pdf. Accessed 15 May 2014.
  2. 2.
    Belot A, Cochat P. Les biothérapies en pédiatrie [Biological therapy in pediatrics] [in French]. Arch Pediatr. 2010;17:1573–82.PubMedGoogle Scholar
  3. 3.
    Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:633–59.PubMedGoogle Scholar
  4. 4.
    Keizer RJ, Huitema ADR, Schellens JHM, Beijen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:493–507.PubMedGoogle Scholar
  5. 5.
    Levy G. Pharmacologic target-mediated drug disposition. Clin. Pharmacol Ther. 1994;56:248–52.PubMedGoogle Scholar
  6. 6.
    Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548–58.PubMedGoogle Scholar
  7. 7.
    Mould DR, Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs. 2010;24:23–39.PubMedGoogle Scholar
  8. 8.
    Tabrizi M, Tseng C, Roskos L. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11:81–8.PubMedGoogle Scholar
  9. 9.
    Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93:2645–68.PubMedGoogle Scholar
  10. 10.
    Strolin Benedetti M, Whomsley R, Baltes EL. Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations. Expert Opin Drug Metab Toxicol. 2005;1:447–71.PubMedGoogle Scholar
  11. 11.
    Alcorn J, McNamara PJ. Pharmacokinetics in the newborn. Adv Drug Deliv Rev. 2003;55:667–86.PubMedGoogle Scholar
  12. 12.
    Stephenson T. How children’s responses to drugs differ from adults. Br J. Clin Pharmacol. 2005;59:670–3.PubMedCentralPubMedGoogle Scholar
  13. 13.
    EMA. European public assessment reports [online database]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124. Accessed 30 Apr 2014.
  14. 14.
  15. 15.
    Cuzzolin L, Zaccaron A, Fanos V. Unlicensed and off-label uses of drugs in paediatrics: a review of the literature. Fundam Clin Pharmacol. 2003;17:125–31.PubMedGoogle Scholar
  16. 16.
    Gillick MR. Controlling off-label medication use. Ann Intern Med. 2009;150:344–7.PubMedGoogle Scholar
  17. 17.
    Prytuła A, Iijima K, Kamei K, Geary D, Gottlich E, Majeed A, et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol. 2010;25:461–8.PubMedGoogle Scholar
  18. 18.
    O’Connor K, Liddle C. Prospective data collection of off-label use of rituximab in Australian public hospitals. Intern Med J. 2013;43:863–70.PubMedGoogle Scholar
  19. 19.
    Liang Y, Zhang L, Gao J, Hu D, Ai Y. Rituximab for children with immune thrombocytopenia: a systematic review. PLoS One. 2012;7:e36698.PubMedCentralPubMedGoogle Scholar
  20. 20.
    Anink J, Otten MH, Prince FHM, Hoppenreijs EPAH, Wulffraat NM, Swart JF, et al. Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch arthritis and biologicals in children register. Rheumatology. 2013;52:712–7.PubMedGoogle Scholar
  21. 21.
    Otten MH, Prince FHM, ten Cate R, van Rossum MAJ, Twilt M, Hoppenreijs EPAH, et al. Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective? Ann Rheum Dis. 2011;70:337–40.PubMedGoogle Scholar
  22. 22.
    Speer ME, Fernandes CJ, Boron M, Groothuis JR. Use of palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis. Pediatr Infect Dis J. 2008;27:559–61.PubMedGoogle Scholar
  23. 23.
    Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008;153:833–8.PubMedCentralPubMedGoogle Scholar
  24. 24.
    Basu B. Ofatumumab for rituximab-resistant nephrotic syndrome. N Engl J Med. 2014;370:1268–70.PubMedGoogle Scholar
  25. 25.
    Steinbrook R. Testing medications in children. N Engl J Med. 2002;347:1462–70.PubMedGoogle Scholar
  26. 26.
    EMA, Paediatric Committee. Medicines for children. Paediatric investigation plans; 2007. http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000302.jsp&mid=WC0b01ac058002d4ea. Accessed 13 May 2014.
  27. 27.
    U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Draft guidance for industry. Pediatric Study Plans: Content of and process for submitting. Initial pediatric study plans and amended pediatric study plans. Draft guidance. July 2013. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM360507.pdf. Accessed 13 May 2014.
  28. 28.
    Zhang X, Hsu J, Brunner H, De Benedetti F, Le Gallo C, Zuber Z, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of tocilizumab (TCZ) in polyarticular-course juvenile idiopathic arthritis (pcJIA). Clin Pharmacol Ther. 2013;93(Suppl 1):S88–9.Google Scholar
  29. 29.
    Johnson TN. The problems in scaling adult drug doses to children. Arch Dis Child. 2008;93:207–11.PubMedGoogle Scholar
  30. 30.
    Shi R, Derendorf H. Pediatric dosing and body size in biotherapeutics. Pharmaceutics. 2010;2:389–418.PubMedCentralGoogle Scholar
  31. 31.
    Anderson BJ, Holford NHG. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303–32.PubMedGoogle Scholar
  32. 32.
    Anderson BJ, Holford NHG. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24:25–36.PubMedGoogle Scholar
  33. 33.
    Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098.PubMedGoogle Scholar
  34. 34.
    Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr. 1978;93:62–6.PubMedGoogle Scholar
  35. 35.
    Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863–71.Google Scholar
  36. 36.
    Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet. 2013;52:83–124.PubMedGoogle Scholar
  37. 37.
    Xu Z, Davis HM, Zhou H. Rational development and utilization of antibody-based therapeutic proteins in pediatrics. Pharmacol Ther. 2013;137:225–47.PubMedGoogle Scholar
  38. 38.
    Richter WF, Bhansali SG, Morris ME. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J. 2012;14:559–70.PubMedCentralPubMedGoogle Scholar
  39. 39.
    Kagan L, Mager DE. Mechanisms of subcutaneous absorption of rituximab in rats. Drug Metab Dispos. 2013;41:248–55.PubMedGoogle Scholar
  40. 40.
    Kuester K, Kloft C. Pharmacokinetics of monoclonal antibodies (part I and II). In: Meibohm B, editor. Pharmacokinetics and pharmacodynamics of biotech drugs: principles and case studies in drug development. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2006. p. 45–91.Google Scholar
  41. 41.
    Lowe PJ, Renard D. Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE. Br J Clin Pharmacol. 2011;72:306–20.PubMedCentralPubMedGoogle Scholar
  42. 42.
    Robbie GJ, Zhao L, Mondick J, Losonsky G, Roskos LK. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother. 2012;56:4927–36.PubMedCentralPubMedGoogle Scholar
  43. 43.
    Krippendorff B-F, Kuester K, Kloft C, Huisinga W. Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis. J Pharmacokinet Pharmacodyn. 2009;36:239–60.PubMedCentralPubMedGoogle Scholar
  44. 44.
    Zhang Y, Pardridge WM. Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. J Neuroimmunol. 2001;114:168–72.PubMedGoogle Scholar
  45. 45.
    Butte NF, Hopkinson JM, Wong WW, O’Brian Smith E, Ellis KJ. Body composition during the first 2 years of life: an updated reference. Pediatr Res. 2000;47:578–85.PubMedGoogle Scholar
  46. 46.
    Ternant D, Mulleman D, Degenne D, Willot S, Guillaumin J-M, Watier H, et al. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit. 2006;28:169–74.PubMedGoogle Scholar
  47. 47.
    Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715–25.PubMedGoogle Scholar
  48. 48.
    Bai S, Jorga K, Xin Y, Jin D, Zheng Y, Damico-Beyer LA, et al. A guide to rational dosing of monoclonal antibodies. Clin Pharmacokinet. 2012;51:119–35.PubMedGoogle Scholar
  49. 49.
    Fasanmade A, Adedokun O, Olson A, Strauss R, Davis H. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol. Ther. 2010;48:297–308.PubMedGoogle Scholar
  50. 50.
    Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM. Pharmacokinetic properties of infliximab in children and adults with crohn’s disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011;33:946–64.PubMedGoogle Scholar
  51. 51.
    Kapel N, Meillet D, Favennec L, Magne D, Raichvarg D, Gobert JG. Evaluation of intestinal clearance and faecal excretion of alpha 1-antiproteinase and immunoglobulins during Crohn’s disease and ulcerative colitis. Eur J Clin Chem Clin Biochem. 1992;30:197–202.PubMedGoogle Scholar
  52. 52.
    Brandse JF, Wildenberg ME, de Bruyn JR, Wolbink G, Lowenberg M, Ponsioen CY, et al. P500 Fecal loss of infliximab as a cause of lack of response in severe inflammatory bowel disease [abstract]. J Crohns Colitis. 2013;7:S210.Google Scholar
  53. 53.
    Struemper H, Cai W. Population pharmacokinetics of belimumab in systemic lupus erythematosus: insights for monoclonal antibody covariate modeling from a large data set [abstract no. 2792]. PAGE 22; 11–14 Jun 2013; Glasgow. http://www.page-meeting.org/?abstract=2792. Accessed 22 Oct 2014.
  54. 54.
    Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Wilkins B, Cole M, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol. 2009;24:67–76.PubMedGoogle Scholar
  55. 55.
    Holt PG, Jones CA. The development of the immune system during pregnancy and early life. Allergy. 2000;55:688–97.PubMedGoogle Scholar
  56. 56.
    Agarwal S, Cunningham-Rundles C. Assessment and clinical interpretation of reduced IgG values. Ann Allergy Asthma Immunol. 2007;99:281–3.PubMedCentralPubMedGoogle Scholar
  57. 57.
    Garcia-Lloret M, McGhee S, Chatila T. Immunoglobulin replacement therapy in children. Immunol Allergy Clin N Am. 2008;28:833–49.Google Scholar
  58. 58.
    Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol. 2009;68:61–76.PubMedCentralPubMedGoogle Scholar
  59. 59.
    Goldman J, Davis H, Zhou H, Kearns G. Infliximab clearance in children: potential association with resting energy expenditure. Ann Paediatr Rheum. 2012;1:120–5.Google Scholar
  60. 60.
    Kovarik JM, Offner G, Broyer M, Niaudet P, Loirat C, Mentser M, et al. A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations. Transplantation. 2002;74:966–71.PubMedGoogle Scholar
  61. 61.
    U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry and FDA staff. Qualification process for drug development tools. Jan 2014. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf. Accessed 14 Feb 2014.
  62. 62.
    Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28:507–32.PubMedGoogle Scholar
  63. 63.
    Weisman LE, Thackray HM, Garcia-Prats JA, Nesin M, Schneider JH, Fretz J, et al. Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrob Agents Chemother. 2009;53:2879–86.PubMedCentralPubMedGoogle Scholar
  64. 64.
    Kokai-Kun JF, Mould D, Weisman L, Bloom B, Eyal F, Polack M, et al. Predicted and measured pagibaximab serum levels in high-risk neonates [poster no. 1380]. Pediatr Res. 2010;68:683.Google Scholar
  65. 65.
    Höcker B, Kovarik JM, Daniel V, Opelz G, Fehrenbach H, Holder M, et al. Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication. Transplantation. 2008;86:1234–40.PubMedGoogle Scholar
  66. 66.
    Nagai T, Gotoh Y, Watarai Y, Tajima T, Arai K, Uchida K. Pharmacokinetics and pharmacodynamics of basiliximab in Japanese pediatric renal transplant patients. Int J Clin Pharmacol Ther. 2010;48:214–23.PubMedGoogle Scholar
  67. 67.
    De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol. 2007;28:482–90.PubMedGoogle Scholar
  68. 68.
    Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2005;20:vi3–9.PubMedGoogle Scholar
  69. 69.
    Niebecker R, Kloft C. Safety of therapeutic monoclonal antibodies. Curr Drug Saf. 2010;5:275–86.PubMedGoogle Scholar
  70. 70.
    Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J. 2012;14:296–302.PubMedCentralPubMedGoogle Scholar
  71. 71.
    U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: immunogenicity assessment for therapeutic protein products. 2014. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338856.pdf. Accessed 22 Oct 2014.
  72. 72.
    Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond R, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol. 2004;2:542–53.PubMedGoogle Scholar
  73. 73.
    Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases. Ann Rheum Dis. 2013;72:165–78.PubMedGoogle Scholar
  74. 74.
    Wang S-L, Ohrmund L, Hauenstein S, Salbato J, Reddy R, Monk P, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods. 2012;382:177–88.PubMedGoogle Scholar
  75. 75.
    Gómez-Mantilla JD, Trocóniz IF, Parra-Guillén Z, Garrido MJ. Review on modeling anti-antibody responses to monoclonal antibodies. J Pharmacokinet Pharmacodyn. Epub 2014 Jul 16.Google Scholar
  76. 76.
    Siegrist C-A, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol. 2009;9:185–94.PubMedGoogle Scholar
  77. 77.
    Angiolillo AL, Yu AL, Reaman G, Ingle AM, Secola R, Adamson PC, et al. A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a children’s oncology group report. Pediatr Blood Cancer. 2009;53:978–83.PubMedCentralPubMedGoogle Scholar
  78. 78.
    Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Haweekins PN, Tran TA, Bader-Meunier B, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis. 2011;70:2095–102.PubMedGoogle Scholar
  79. 79.
    Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360:2416–25.PubMedGoogle Scholar
  80. 80.
    Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396–406.PubMedGoogle Scholar
  81. 81.
    Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64:557–67.PubMedGoogle Scholar
  82. 82.
    Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, et al. Infliximab (Remicade) therapy in the treatment of pediatric Crohn’s disease. Am J Gastroenterol. 2003;98:833–8.PubMedGoogle Scholar
  83. 83.
    Hadigan C, Baldassano R, Braegger CP, Vasiliauskis E, Escher JC, Sinaasappel M, et al. Pharmacokinetics of infliximab (Anti-TNF) in children with Crohn’s disease: a multicenter trial [abstract]. J Pediatr Gastroenterol Nutr. 1999;29:525.Google Scholar
  84. 84.
    Abarca K, Jung E, Fernández P, Zhao L, Harris B, Connor EM, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children. Pediatr Infect Dis J. 2009;28:267–72.PubMedGoogle Scholar
  85. 85.
    Weisman LE, Thackray HM, Steinhorn RH, Walsh WF, Lassiter HA, Dhanireddy R, et al. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics. 2011;128:271–9.PubMedGoogle Scholar
  86. 86.
    Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J, Corey L. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis. 2001;184:350–4.PubMedGoogle Scholar
  87. 87.
    Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810–20.PubMedGoogle Scholar
  88. 88.
    Imagawa T, Takei S, Umebayashi H, Yamaguchi K, Itoh Y, Kawai T, et al. Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin Rheumatol. 2012;31:1713–21.PubMedCentralPubMedGoogle Scholar
  89. 89.
    Hyams JS, Griffiths A, Markowitz J, Baldassano RN, Faubion WA, Colletti RB, et al. Safety and efficacy of adalimumab for moderate to severe Crohn’s disease in children. Gastroenterology. 2012;143:365–74.PubMedGoogle Scholar
  90. 90.
    Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, et al. Phase 1 trial of adalimumab in focal segmental glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis. 2010;55:50–60.PubMedCentralPubMedGoogle Scholar
  91. 91.
    Kingsbury DJ, Bader-Meunier B, Patel G, Arora V, Kalabic J, Kupper H. Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2–4 years. Clin. Rheumatol. 2014;33:4133–41.Google Scholar
  92. 92.
    Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a children’s oncology group study. J Clin Oncol. 2008;26:399–405.PubMedGoogle Scholar
  93. 93.
    Trippett TM, Herzog C, Whitlock JA, Wolff J, Kuttesch J, Bagatell R, et al. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators’ consortium. J Clin Oncol. 2009;27:5102–8.PubMedGoogle Scholar
  94. 94.
    Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30:256–62.PubMedCentralPubMedGoogle Scholar
  95. 95.
    Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169–81.PubMedGoogle Scholar
  96. 96.
    Buckwalter M, Dowell JA, Korth-Bradley J, Gorovits B, Mayer PR. Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Pharmacol. 2004;44:873–80.PubMedGoogle Scholar
  97. 97.
    Candon S, Mosca A, Ruemmele F, Goulet O, Chatenoud L, Cézard J-P. Clinical and biological consequences of immunization to infliximab in pediatric Crohn’s disease. Clin Immunol. 2006;118:11–9.PubMedGoogle Scholar
  98. 98.
    Adedokun OJ, Xu Z, Padgett L, Blank M, Johanns J, Griffiths A, et al. Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study. Inflamm Bowel Dis. 2013;19:2753–62.PubMedGoogle Scholar
  99. 99.
    Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology. 2007;132:863–73 (quiz 1165–6).PubMedGoogle Scholar
  100. 100.
    Hyams J, Walters TD, Crandall W, Kugathasan S, Griffiths A, Blank M, et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extension. Curr Med Res Opin. 2011;27:651–62.PubMedGoogle Scholar
  101. 101.
    Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56:3096–106.PubMedGoogle Scholar
  102. 102.
    Fernández P, Trenholme A, Abarca K, Griffin MP, Hultquist M, Harris B, et al. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season. BMC Pediatr. 2010;10:38.PubMedCentralPubMedGoogle Scholar
  103. 103.
    Grundy J, Pan W, Kugathasan S, Nagpala F, Hilton D, Taylor J, et al. Pharmacokinetics and pharmacodynamics of natalizumab in a phase 2 study of adolescent patients with Crohn’s disease. J Pediatr Gastroenterol Nutr. 2005;41:493–563.Google Scholar
  104. 104.
    Hyams JS, Wilson DC, Thomas A, Heuschkel R, Mitton S, Mitchell B, et al. Natalizumab therapy for moderate to severe Crohn disease in adolescents. J Pediatr Gastroenterol Nutr. 2007;44:185–91.PubMedGoogle Scholar
  105. 105.
    Sáez-Llorens X, Moreno MT, Ramilo O, Sánchez PJ, Top FH, Connor EM. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J. 2004;23:707–12.PubMedGoogle Scholar
  106. 106.
    Sáez-Llorens X, Castaño E, Null D, Steichen J, Sánchez PJ, Ramilo O, et al. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group. Pediatr Infect Dis J. 1998;17:787–91.PubMedGoogle Scholar
  107. 107.
    Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sánchez PJ, Steichen J, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J. 1998;17:110–5.PubMedGoogle Scholar
  108. 108.
    Barth MJ, Goldman S, Smith L, Perkins S, Shiramizu B, Gross TG, et al. Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a children’s oncology group report. Br J Haematol. 2013;162:678–83.PubMedCentralPubMedGoogle Scholar
  109. 109.
    Pranzatelli MR, Tate ED, Verhulst SJ, Bertolone SJ, Bhatla D, Granger M, et al. Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol. 2010;32:e167–72.PubMedGoogle Scholar
  110. 110.
    Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol. 2009;24:1321–8.PubMedGoogle Scholar
  111. 111.
    Brunner H, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, et al. Efficacy and safety of tocilizumab in patients with polyarticular juvenile idiopathic arthritis: data from a phase 3 trial [abstract no. 1597]. Arthritis Rheum. 2012;64:s682.Google Scholar
  112. 112.
    Woo P, Wilkinson N, Prieur A-M, Southwood T, Leone V, Livermore P, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7:R1281–8.PubMedCentralPubMedGoogle Scholar
  113. 113.
    Zhang X, Morcos PN, Saito T, Terao K. Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis. Expert Rev Clin Pharmacol. 2013;6(2):123–37.PubMedGoogle Scholar
  114. 114.
    Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006.PubMedGoogle Scholar
  115. 115.
    Zhang X, Morcos PN, De Benedetti F, Brunner H, Ruperto N, Schaefer F, et al. Pharmacokinetics and pharmacodynamics of tocilizumab in systemic juvenile idiopathic arthritis [abstract]. Pharmacotherapy. 2011;31(10):381e.Google Scholar
  116. 116.
    Kakkar T, Sung C, Gibiansky L, Vu T, Narayanan A, Lin S-L, et al. Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. Pharm Res. 2011;28:2530–42.PubMedGoogle Scholar
  117. 117.
    Turner DC, Navid F, Daw NC, Mao S, Wu J, Santana VM, et al. Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing. Clin Cancer Res. 2014;20:2783–92.PubMedGoogle Scholar
  118. 118.
    Pescovitz MD, Knechtle S, Alexander SR, Colombani P, Nevins T, Nieforth K, et al. Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. Pediatr Transplant. 2008;12:447–55.PubMedGoogle Scholar
  119. 119.
    Xu Z, Mould D, Hu C, Ford J, Keen M, Davis HM, et al. Population pharmacokinetic analysis of infliximab in pediatrics using integrated data from six clinical trials. Clin Pharmacol Drug Dev. 2012;4:203.Google Scholar
  120. 120.
    Zhao L, Roskos L, Griffin P, Losonsky G, Jallal GB, Robbie G. 891 Population pharmacokinetics analysis of motavizumab in children at risk for respiratory syncytial virus infection. Pediatr. Res. 2010;68:447.Google Scholar
  121. 121.
    Marian M, Sun Y-N, Sinclair D, Kenkare S, Sallas W, Mortensen D, et al. PI-23 Clincal pharmacokinetics (PK) and IgE pharmacodynamics (PD) of omalizumab, a recombinant humanized monoclonal antibody to IgE. Clin Pharmacol Ther. 2001;69:P7.Google Scholar
  122. 122.
    Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood. 2006;107:2639–42.PubMedCentralPubMedGoogle Scholar
  123. 123.
    Hagopian W, Ferry RJ, Sherry N, Carlin D, Bonvini E, Johnson S, et al. Teplizumab preserves C-Peptide in recent-onset type 1 diabetes. Two-year results from the randomized, placebo-controlled Protégé trial. Diabetes. 2013;62:3901–8.PubMedCentralPubMedGoogle Scholar
  124. 124.
    Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ, et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet. 2011;378:487–97.PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Helena Edlund
    • 1
    • 2
  • Johanna Melin
    • 1
    • 2
  • Zinnia P. Parra-Guillen
    • 1
  • Charlotte Kloft
    • 1
    Email author
  1. 1.Department of Clinical Pharmacy and Biochemistry, Institute of PharmacyFreie Universitaet BerlinBerlinGermany
  2. 2.Graduate Research Training Program, PharMetrXBerlinGermany

Personalised recommendations